Insulin Glargine
Insulin Glulisine
Powerful
Partners
In
glycaemic control.
Insulin Glargine
24-hour basal coverage. Day after day.
I n s u l i n G l u l i s i n e
T h e s p e e d y o u n e e d . W h e n y o u n e e d i t .
SCHEDULING STATUS:
S3
PROPRIETARY NAME
(and dosage form):
LANTUS
®
(solution for injection).
COMPOSITION:
Each ml of the solution for injection contains 3.64 mg of the active ingredient insulin glargine,
corresponding to 100 U human insulin.
REGISTRATION NUMBER:
34/21.1/0248.
NAME AND BUSINESS ADDRESS OF THE APPLICANT:
sanofi-aventis south africa (pty) ltd, 2 Bond Street, Midrand, 1685.
Reg. No. 1996/10381/07.
SCHEDULING STATUS:
S3
PROPRIETARY NAME AND DOSAGE FORM:
APIDRA
TM
solution for injection.
COMPOSITION:
1 ml contains 3,5 mg insulin glulisine, corresponding to 100 U human insulin.
REGISTRATION NUMBER:
A38/21.1/0506
NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION:
sanofi-aventis south africa (pty) ltd, 2 Bond Street, Midrand, 1685. Reg. No. 1996/10381/07.
APPLICANT:
sanofi-aventis south africa (pty) ltd, 2 Bond Street, Midrand, 1685. Reg. No. 1996/10381/07.
ZA.GLA.09.04.13
EURO
RSCG 3596/E
